Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | RORC | P51449 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | FAAH | O00519 | 1/20 | 0.30 |
| ▸ | NAAA | Q02083 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17162718 | 0.85 | SMN1; SMN2 (0.39) | SMN1; SMN2CNR2TSHRPARP1NPSR1 | |
| SCHEMBL3212643 | 0.83 | SMN1; SMN2 (0.39) | SMN1; SMN2CNR2TSHRPARP1NPSR1 | |
| SCHEMBL13223504 | 0.81 | SMN1; SMN2 (0.38) | SMN1; SMN2CNR2TSHRPARP1NPSR1 | |
| SCHEMBL3542786 | 0.80 | SMN1; SMN2 (0.45) | SMN1; SMN2CNR2TSHRPARP1RORC | |
| SCHEMBL10738631 | 0.79 | SMN1; SMN2 (0.39) | SMN1; SMN2CNR2PARP1 | |
| SCHEMBL3210068 | 0.79 | SMN1; SMN2 (0.44) | SMN1; SMN2CNR2TSHRPARP1NPSR1 | |
| SCHEMBL10734073 | 0.79 | SMN1; SMN2 (0.37) | SMN1; SMN2CNR2PARP1RORC | |
| SCHEMBL1583189 | 0.78 | POLB (0.41) | SMN1; SMN2CNR2TSHRPOLBKMT2A | |
| SCHEMBL1632144 | 0.76 | MAPK1 (0.41) | SMN1; SMN2CNR2ALDH1A1 | |
| SCHEMBL9234226 | 0.74 | OPRM1 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101842373-B | 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives as cathepsin inhibitors | ORGANON NV | 2013-12-18 | — | — | CN | disclosed |
| US-7932251-B2 | 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives | N.V. ORGANON (NL) | 2011-04-26 | — | — | US | disclosed |
| EP-2178873-B1 | 6-PHENYL-1H-IMIDAZO[4,5-C]PYRIDINE-4-CARBONITRILE DERIVATIVES AS CATHEPSIN INHIBITORS | ORGANON NV (NL) | 2010-12-22 | — | — | EP | disclosed |
| CN-101842373-A | 6-phenyl-1H-imidazo [4,5-c] pyridine-4-6-carbonitrile derivatives as cathepsin inhibitors | ORGANON NV | 2010-09-22 | — | — | CN | disclosed |
| EP-2178873-A1 | 6-PHENYL-1H-IMIDAZO[4,5-C]PYRIDINE-4-CARBONITRILE DERIVATIVES AS CATHEPSIN INHIBITORS | N.V. Organon (NL) | 2010-04-28 | — | — | EP | disclosed |
| US-20090099172-A1 | 6-PHENYL-1H-IMIDAZO[4,5-c]PYRIDINE-4-CARBONITRILE DERIVATIVES | N. V. ORGANON | 2009-04-16 | — | — | US | disclosed |
| WO-2009010491-A1 | 6-PHENYL-1H-IMIDAZO[4,5-C]PYRIDINE-4-CARBONITRILE DERIVATIVES AS CATHEPSIN INHIBITORS | N.V. ORGANON (NL) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099172-A1 | 6-PHENYL-1H-IMIDAZO[4,5-c]PYRIDINE-4-CARBONITRILE DERIVATIVES | CTSS, CTSV, CTSB | SMN1; SMN2 4025/4885CNR2 111/4885TSHR 4483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.